Adrenomed AG
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Oct 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 13, 2026The maintenance fee for Method of Modulating the Adrenomedullin (ADM) Activity of a Patient by Administering to the Patient an Anti-Adm Antibody or Fragment Thereof That Specifically Binds to Mature Human Adm (US 11,673,949) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 1 fee due Mar 22, 2027The maintenance fee for Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition (US 9,140,696) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
- 1 fee due Oct 5, 2027The maintenance fee for Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy (US 9,304,127) comes due Oct 5, 2027. Unpaid by Apr 5, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,829,494 | Methods of treatment using ADM antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 9,140,696 | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition In force · From the USPTO record | In force | From the USPTO record | |
| US 9,304,127 | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy In force · From the USPTO record | In force | From the USPTO record | |
| US 9,402,900 | Methods of Modulating Adrenomedullin by Administering an Anti-Adrenomedullin (ADM) Antibody In force · Medium confidence | In force | Medium confidence | |
| US 10,221,238 | A Method of Modulating the Activity of Adrenomedullin in a Subject in Need of Therapeutic Intervention for Organ Dysfunction or Organ Failure Associated with Adranomedullin (ADM) Activity by Administering an Anti-Adrenomedullin (ADM) Antibody or an Anti-Adm Antibody Fragment to the Subject In force · Medium confidence | In force | Medium confidence | |
| US 10,227,405 | Methods of Modulating the Activity of Adrenomedullin in a Subject in Need of Regulation of Fluid Balance by Administering an Anti-Adrenomedullin (ADM) Antibody or an Anti-Adm Antibody Fragment In force · Medium confidence | In force | Medium confidence | |
| US 10,800,842 | Anti-Adrenomedullin (ADM) Monoclonal Antibodies and Anti-Adm Monoclonal Antibody Fragments That Bind to Adrenomedullin In force · Medium confidence | In force | Medium confidence | |
| US 11,673,949 | Method of Modulating the Adrenomedullin (ADM) Activity of a Patient by Administering to the Patient an Anti-Adm Antibody or Fragment Thereof That Specifically Binds to Mature Human Adm In force · Medium confidence | In force | Medium confidence | |
| US 12,338,281 | Anti-Adrenomedullin Antibodies and Pharmaceutical Compositions Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,715,911 | Anti-Adrenomedullin (ADM) Antibody or Anti-Adm Antibody Fragment or Anti-Adm Non-Ig Scaffold for Use in Intervention and Therapy of Congestion in a Patient in Need Thereof In force · Medium confidence | In force | Medium confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 2 abandoned · 3 no status recorded